Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

SML2281

Sigma-Aldrich

BAY 60-2770

≥98% (HPLC)

Sinonimo/i:

4-[((4-Carboxy-butyl)-{2-[5-fluoro-2-(4′-trifluoromethyl-biphenyl-4-ylmethoxy)-phenyl]-ethyl}-amino)-methyl]-benzoic acid, 4-[[(4-Carboxybutyl)[2-[5-fluoro-2-[[4′-(trifluoromethyl)[1,1′-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]benzoic acid

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C35H33F4NO5
Numero CAS:
1027642-43-8
Peso molecolare:
623.63
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Stato

powder

Colore

white to beige

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

2-8°C

Stringa SMILE

FC1=CC=C(OCC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)C(CCN(CC4=CC=C(C(O)=O)C=C4)CCCCC(O)=O)=C1

Azioni biochim/fisiol

BAY 60-2770 is a potent and selective soluble guanylyl cyclase (sGC) heme-independent activator that protects sGC from heme oxidation in smooth muscle tissues. BAY 60-2770 provides cardioprotection and limits the infarct size in rat ischaemia-reperfusion model. Also BAY 60-2770 Ameliorates of urethra dysfunction in high-fat fed obese mice.
Structurally, BAY 60-2770 comprises fluoro and trifluoromethyl moieties. It stimulates in vitro expressed α2/β1 isoform of nitric oxide sensitive guanylyl cyclase (NOsGC). BAY 60-2770 is reported to be effective in treating liver fibrosis and in lowering arterial pressures (both pulmonary and systemic) in animal studies. It elicits anti-aggregating and anti-adhesive effects on platelets and may have therapeutic potential to treat atherothrombotic events.

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Camila B Mendes-Silverio et al.
PloS one, 7(11), e47223-e47223 (2012-11-13)
Nitric oxide-independent soluble guanylyl cyclase (sGC) activators reactivate the haem-oxidized enzyme in vascular diseases. This study was undertaken to investigate the anti-platelet mechanisms of the haem-independent sGC activator BAY 60-2770 in human washed platelets. The hypothesis that sGC oxidation potentiates
Eduardo C Alexandre et al.
The Journal of pharmacology and experimental therapeutics, 349(1), 2-9 (2014-01-15)
Obesity has emerged as a major contributing risk factor for overactive bladder (OAB), but no study examined urethral smooth muscle (USM) dysfunction as a predisposing factor to obesity-induced OAB. This study investigated the USM relaxant machinery in obese mice and
Justin S Bice et al.
Cardiovascular research, 101(2), 220-228 (2013-11-22)
Guanylyl cyclase-cyclic guanosine monophosphate signalling plays an important role in endogenous cardioprotective signalling. The aim was to assess the potential of direct pharmacological activation and stimulation of soluble guanylyl cyclase, targeting different redox states of the enzyme, to limit myocardial
Alexander Kollau et al.
Molecular pharmacology, 93(2), 73-78 (2017-11-16)
Belonging to the class of so-called soluble guanylate cyclase (sGC) activators, cinaciguat and BAY 60-2770 are interesting therapeutic tools for the treatment of various cardiovascular pathologies. The drugs are supposed to preferentially stimulate oxidized or heme-depleted, but not native sGC.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.